Silencing of hepatitis C virus replication by a non-viral vector based on solid lipid nanoparticles containing a shRNA targeted to the internal ribosome entry site (IRES)

Colloids and Surfaces B: Biointerfaces

Volumn 146, Issue , 2016, Pages 808-817

  Torrecilla, Josune ^a   del Pozo Rodríguez, Ana ^a   Solinís, María Ángeles ^a   Apaolaza, Paola S ^a   Berzal Herranz, Beatriz ^b   Romero López, Cristina ^b   Berzal Herranz, Alfredo ^b   Rodríguez Gascón, Alicia ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

HCV IRES; Hepatitis C; Hyaluronic acid; RNAi; shRNA; Solid lipid nanoparticles

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; BIOCOMPATIBILITY; CELLS; CYTOLOGY; DISEASES; HYALURONIC ACID; MACROMOLECULES; MOLECULAR BIOLOGY; NANOPARTICLES; ORGANIC ACIDS; VIRUSES;

HCV-IRES; HEPATITIS C; RNAI; SHRNA; SOLID LIPID NANOPARTICLE (SLN);

VECTORS;

HERMES ANTIGEN; HYALURONIC ACID; NANOCARRIER; PROTAMINE; SHORT HAIRPIN RNA; SOLID LIPID NANOPARTICLE; VIRUS RNA; ANTIVIRUS AGENT; INTERNAL RIBOSOME ENTRY SITE; LIPID; NANOPARTICLE; SMALL INTERFERING RNA;

ARTICLE; CELL INTERACTION; CELL TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; ENDOCYTOSIS; ERYTHROCYTE; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; REPLICON; VIRUS REPLICATION; ZETA POTENTIAL; CELL SURVIVAL; CHEMISTRY; GENETICS; HEPACIVIRUS; HEPATITIS C; LIVER CELL CARCINOMA; LIVER TUMOR; REPORTER GENE; TUMOR CELL CULTURE; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; GENES, REPORTER; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERNAL RIBOSOME ENTRY SITES; LIPIDS; LIVER NEOPLASMS; NANOPARTICLES; REPLICON; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 84989287594     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2016.07.026     Document Type: Article

References (44)

1. [1] Tai, A.W., Chung, R.T., Treatment failure in hepatitis C: mechanisms of non-response. J. Hepatol. 50 (2009), 412–420, 10.1016/j.jhep.2008.11.010.
2. [2] Pungpapong, S., Aqel, B., Leise, M., Werner, K.T., Murphy, J.L., Henry, T.M., Ryland, K., Chervenak, A.E., Watt, K.D., Vargas, H.E., Keaveny, A.P., Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 61 (2015), 1880–1886, 10.1002/hep.27770.
3. [3] Watanabe, T., Hatakeyama, H., Matsuda-Yasui, C., Sato, Y., Sudoh, M., Takagi, A., Hirata, Y., Ohtsuki, T., Arai, M., Inoue, K., Harashima, H., Kohara, M., In vivo therapeutic potential of dicer-hunting siRNAs targeting infectious hepatitis C virus. Sci. Rep., 4, 2014, 4750, 10.1038/srep04750.
4. [4] Romano, K.P., Ali, A., Aydin, C., Soumana, D., Özen, A., Deveau, L.M., Silver, C., Cao, H., Newton, A., Petropoulos, C.J., Huang, W., Schiffer, C.A., The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog., 8, 2012, e1002832, 10.1371/journal.ppat.1002832.
5. [5] Chandra, P.K., Kundu, A.K., Hazari, S., Chandra, S., Bao, L., Ooms, T., Morris, G.F., Wu, T., Mandal, T.K., Dash, S., Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes. Mol. Ther. 20 (2012), 1724–1736, 10.1038/mt.2012.107.
6. [6] Romero-López, C., Sánchez-Luque, F.J., Berzal-Herranz, A., Targets and tools: recent advances in the development of anti HCV nucleic acids. Infect. Disord. Drug Targets 6 (2006), 121–145.
7. [7] Dibrov, S.M., Parsons, J., Carnevali, M., Zhou, S., Rynearson, K.D., Ding, K., Garcia Sega, E., Brunn, N.D., Boerneke, M.A., Castaldi, M.P., Hermann, T., Hepatitis C virus translation inhibitors targeting the internal ribosomal entry site. J. Med. Chem. 57 (2014), 1694–1707, 10.1021/jm401312n.
8. [8] Davis, D.R., Seth, P.P., Therapeutic targeting of HCV internal ribosomal entry site RNA. Antivir. Chem. Chemother. 21 (2011), 117–128, 10.3851/IMP1693.
9. [9] Pei, Z., Shi, G., Kondo, S., Ito, M., Maekawa, A., Suzuki, M., Saito, I., Suzuki, T., Kanegae, Y., Adenovirus vectors lacking virus-associated RNA expression enhance shRNA activity to suppress hepatitis C virus replication. Sci. Rep., 3, 2013, 3575, 10.1038/srep03575.
10. [10] Torrecilla, J., Rodríguez-Gascón, A., Solinís, M.Á., del Pozo-Rodríguez, A., Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives. Biomed. Res. Int., 2014, 2014, 161794, 10.1155/2014/161794.
11. [11] Jin, X., Sun, T., Zhao, C., Zheng, Y., Zhang, Y., Cai, W., He, Q., Taira, K., Zhang, L., Zhou, D., Strand antagonism in RNAi: an explanation of differences in potency between intracellularly expressed siRNA and shRNA. Nucleic Acids Res. 40 (2012), 1797–1806, 10.1093/nar/gkr927.
12. [12] A. Rodríguez-Gascón, M.Á. Solinís, A. del Pozo-Rodríguez, D. Delgado, J.L. Pedraz, Inventors. University of the Basque Country UPV/EHU. Lipid nanoparticles for gene therapy. WO2011015701 (A3), ES2351756 (B1). 2012.
13. [13] A. Rodríguez-Gascón, M.Á. Solinís, del A. Pozo-Rodríguez, D. Delgado, E. Fernández, Inventors. University of the Basque Country UPV/EHU and Universidad Miguel Hernández de Elche. Lipid nanoparticles for treating ocular diseases. WO2011015701 (A3), ES2385080 (B1). 2012.
14. [14] Rodríguez-Gascón, A., del Pozo-Rodríguez, A., Solinís, M.Á., Non-viral delivery systems in gene therapy. Martin, F., (eds.) Gene Therapy—Tools and Potential Applications (Intech), 2013, 3–33.
15. [15] Torrecilla, J., del Pozo-Rodríguez, A., Apaolaza, P.S., Solinís, M.Á., Rodríguez-Gascón, A., Solid lipid nanoparticles as non-viral vector for the treatment of chronic hepatitis C by RNA interference. Int. J. Pharm. 479 (2015), 181–188, 10.1016/j.ijpharm.2014.12.047.
16. [16] Lohmann, V., Körner, F., Koch, J., Herian, U., Theilmann, L., Bartenschlager, R., Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999), 110–113.
17. [17] Prabhu, R., Garry, R.F., Dash, S., Small interfering RNA targeted to stem-loop II of the 5' untranslated region effectively inhibits expression of six HCV genotypes. Virol. J., 3, 2006, 100.
18. [18] Larrea, E., Aldabe, R., Molano, E., Fernandez-Rodriguez, C.M., Ametzazurra, A., Civeira, M.P., Prieto, J., Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies. Gut 55 (2006), 1188–1196.
19. [19] del Pozo-Rodríguez, A., Delgado, D., Solinís, M.A., Gascón, A.R., Pedraz, J.L., Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int. J. Pharm. 339 (2007), 261–268.
20. [20] Romero-López, C., Díaz-González, R., Barroso-del Jesus, A., Berzal-Herranz, A., Inhibition of hepatitis C virus replication and internal ribosome entry site-dependent translation by an RNA molecule. J. Gen. Virol. 90 (2009), 1659–1669, 10.1099/vir.0.008821-0.
21. [21] Marton, S., Berzal-Herranz, B., Garmendia, E., Cueto, F.J., Berzal-Herranz, A., Anti-HCV RNA aptamers targeting the genomic cis-acting replication element. Pharmaceuticals 5 (2011), 49–60, 10.3390/ph5010049.
22. [22] Martell, M., Gómez, J., Esteban, J.I., Sauleda, S., Quer, J., Cabot, B., Esteban, R., Guardia, J., High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J. Clin. Microbiol. 37 (1999), 327–332.
23. [23] Barroso-del Jesus, A., Romero-López, C., Lucena-Aguilar, G., Melen, G.J., Sanchez, L., Ligero, G., Berzal-Herranz, A., Menendez, P., Embryonic stem cell-specific miR302-367 cluster: human gene structure and functional characterization of its core promoter. Mol. Cell Biol. 28 (2008), 6609–6619, 10.1128/MCB.00398-08.
24. [24] del Pozo-Rodríguez, A., Delgado, D., Solinís, M.A., Gascón, A.R., Pedraz, J.L., Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int. J. Pharm. 360 (2008), 177–183, 10.1016/j.ijpharm.2008.04.023.
25. [25] Apaolaza, P.S., Delgado, D., del Pozo-Rodríguez, A., Gascón, A.R., Solinís, M.Á., A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases. Int. J. Pharm. 465 (2014), 413–426, 10.1016/j.ijpharm.2014.02.038.
26. [26] Zinchuk, V., Grossenbacher-Zinchuk, O., Quantitative colocalization analysis of fluorescence microscopy images. Curr. Protoc. Cell Biol. 62 (2014), 1–14, 10.1002/0471143030.cb0419s62.
27. [27] Liu, Y., Kong, M., Cheng, X.J., Wang, Q.Q., Jiang, L.M., Chen, X.G., Self-assembled nanoparticles based on amphiphilic chitosan derivative and hyaluronic acid for gene delivery. Carbohydr. Polym. 94 (2013), 309–316, 10.1016/j.carbpol.2012.12.058.
28. [28] Delgado, D., Gascón, A.R., Del Pozo-Rodríguez, A., Echevarría, E., Ruiz de Garibay, A.P., Rodríguez, J.M., Solinís, M.Á., Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice. Int. J. Pharm. 425 (2012), 35–43, 10.1016/j.ijpharm.2011.12.052.
29. [29] Ruiz de Garibay, A.P., Delgado, D., Del Pozo-Rodríguez, A., Á. Solinís, M., Gascón, A.R., Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy. Drug Des. Devel. Ther. 6 (2012), 303–310, 10.2147/DDDT.S36131.
30. [30] Delgado, D., del Pozo-Rodríguez, A., Solinís, M.Á., Rodríguez-Gascón, A., Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway. Eur. J. Pharm. Biopharm. 79 (2011), 495–502, 10.1016/j.ejpb.2011.06.005.
31. [31] de la Fuente, M., Seijo, B., Alonso, M.J., Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest. Ophthalmol. Vis. Sci. 49 (2008), 2016–2024, 10.1167/iovs.07-1077.
32. [32] Romero-López, C., Berzal-Herranz, A., The functional RNA domain 5BSL3.2 within the NS5B coding sequence influences hepatitis C virus IRES-mediated translation. Cell Mol. Life Sci. 69 (2012), 103–113, 10.1007/s00018-011-0729-z.
33. [33] Khalil, I.A., Kogure, K., Akita, H., Harashima, H., Uptake pathways and subsequent intracellular trafficking in non-viral gene delivery. Pharmacol. Rev. 58 (2006), 32–45.
34. [34] Ruiz de Garibay, A.P., Solinís Aspiazu, M.Á., Rodríguez Gascón, A., Ganjian, H., Fuchs, R., Role of endocytic uptake in transfection efficiency of solid lipid nanoparticles-based non-viral vectors. J. Gene Med. 15 (2013), 427–440, 10.1002/jgm.2749.
35. [35] Greyner, H.J., Wiraszka, T., Zhang, L.S., Petroll, W.M., Mummert, M.E., Inducible macropinocytosis of hyaluronan in B16-F10 melanoma cells. Matrix Biol. 29 (2010), 503–510, 10.1016/j.matbio.2010.06.004.
36. [36] Knudson, W., Chow, G., Knudson, C.B., CD44-mediated uptake and degradation of hyaluronan. Matrix Biol. 21 (2002), 15–23.
37. [37] Yamada, Y., Hashida, M., Harashima, H., Hyaluronic acid controls the uptake pathway and intracellular trafficking of an octaarginine-modified gene vector in CD44 positive- and CD44 negative-cells. Biomaterials 52 (2015), 189–198, 10.1016/j.biomaterials.2015.02.027.
38. [38] de la Fuente, M., Seijo, B., Alonso, M.J., Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Ther. 15 (2008), 668–676, 10.1038/gt.2008.16.
39. [39] Wojcicki, A.D., Hillaireau, H., Nascimento, T.L., Arpicco, S., Taverna, M., Ribes, S., Bourge, M., Nicolas, V., Bochot, A., Vauthier, C., Tsapis, N., Fattal, E., Hyaluronic acid-bearing lipoplexes: physico-chemical characterization and in vitro targeting of the CD44 receptor. J. Control. Release 162 (2012), 545–552, 10.1016/j.jconrel.2012.07.015.
40. [40] Islam, M.A., Firdous, J., Choi, Y.J., Yun, C.H., Cho, C.S., Regulation of endocytosis by non-viral vectors for efficient gene activity. J. Biomed. Nanotechnol. 10 (2014), 67–80.
41. [41] del Pozo-Rodríguez, A., Pujals, S., Delgado, D., Solinís, M.A., ascón, A.R.G., Giralt, E., Pedraz, J.L., A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors. J. Control. Release 133 (2009), 52–59, 10.1016/j.jconrel.2008.09.004.
42. [42] del Pozo-Rodríguez, A., Delgado, D., Solinís, M.A., Pedraz, J.L., Echevarría, E., Rodríguez, J.M., Gascón, A.R., Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration. Int. J. Pharm. 385 (2010), 157–162, 10.1016/j.ijpharm.2009.10.020.
43. [43] Delgado, D., del Pozo-Rodríguez, A., Solinís, M.A., Bartkowiak, A., Rodríguez-Gascón, A., New gene delivery system based on oligochitosan and solid lipid nanoparticles: ‘in vitro' and ‘in vivo' evaluation. Eur. J. Pharm. Sci. 50 (2013), 484–491, 10.1016/j.ejps.2013.08.013.
44. [44] Kurosaki, T., Kitahara, T., Fumoto, S., Nishida, K., Yamamoto, K., Nakagawa, H., Kodama, Y., Higuchi, N., Nakamura, T., Sasaki, H., Chondroitin sulfate capsule system for efficient and secure gene delivery. J. Pharm. Pharm. Sci. 13 (2010), 351–361.